7.6 – References
- 1112. 1314. Nava-Mesa, M. O., eJimenez-Diaz, L., eYajeya, J. & Navarro-Lopez, J. D. GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer Disease. Frontiers in Cellular Neuroscience 8, (2014).
- 20113 Fetal Alcohol Spectrum Disorders FASD. CAMH https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/fetal-alcohol-spectrum-disorder.
- Alvarez, A., Opazo, C., Alarcón, R., Garrido, J. & Inestrosa, N. C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272, 348–361 (1997).
- Amarendran, V. & Abam, D. Benzodiazepines and opioids- A volatile combination. 26.
- Arenaza-Urquijo, E. M., Wirth, M. & Chételat, G. Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease. Front. Aging Neurosci. 7, (2015).
- Banerjee, S. et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378, 403–411 (2011).
- Carvajal, F. J. & Inestrosa, N. C. Interactions of AChE with Aβ Aggregates in Alzheimer’s Brain: Therapeutic Relevance of IDN 5706. Front. Mol. Neurosci. 4, (2011).
- Cholinesterase inhibitors | British Columbia Medical Journal. https://www.bcmj.org/articles/cholinesterase-inhibitors.
- Dou, X. et al. L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis. The FASEB Journal 32, 1364–1374 (2018).
- Dou, X., Lee, J. Y. & Charness, M. E. Neuroprotective Peptide NAPVSIPQ Antagonizes Ethanol Inhibition of L1 Adhesion by Promoting the Dissociation of L1 and Ankyrin-G. Biological Psychiatry (2019) doi:10.1016/j.biopsych.2019.08.020.
- Gonzales, M. M. et al. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Int J Geriatr Psychiatry 33, 1305–1311 (2018).
- Gozes, I., Ivashko-Pachima, Y. & Sayas, C. L. ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect. Front Mol Neurosci 11, (2018).
- Gozes, I. NAP (Davunetide) Provides Functional and Structural Neuroprotection. https://www.ingentaconnect.com/content/ben/cpd/2011/00000017/00000010/art00009 (2011) doi:info:doi/10.2174/138161211795589373.
- Heimesaat, M. M., Giladi, E., Kühl, A. A., Bereswill, S. & Gozes, I. The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. Peptides 101, 1–9 (2018).
- Ivashko-Pachima, Y., Maor-Nof, M. & Gozes, I. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLOS ONE 14, e0213666 (2019).
- Klimova, B., Maresova, P. & Kuca, K. Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer’s Disease with Respect to the Rising Treatment Costs. Curr. Alzheimer Res. 13, 1249–1258 (2016).
- Lanctôt, K. L., Rajaram, R. D. & Herrmann, N. Review: Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord 2, 163–180 (2009).
- Lipton, S. A. The molecular basis of memantine action in Alzheimer’s disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2, 155–165 (2005).
- Mattson, M. P. et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376–389 (1992).
- Mechanism of action of antipsychotic drugs: (a) overproduction of dopamine; (b) antipsychotic medica – Biology Forums Gallery. https://biology-forums.com/index.php?action=gallery;sa=view;id=19650
- Pompili, M. et al. Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview. International Journal of Molecular Sciences 17, 1700 (2016).
- Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47, 27–38 (2002).
- Paterson, R. W. et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alz Res Therapy 10, 32 (2018).
- Rafii, M. S. & Aisen, P. S. Recent developments in Alzheimer’s disease therapeutics. BMC Med 7, 7 (2009).
- Schelke, M. W. et al. Nutritional interventions for Alzheimer’s prevention: a clinical precision medicine approach. Annals of the New York Academy of Sciences 1367, 50–56 (2016).
- Waqar, M. & Batool, S. In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease. J Venom Anim Toxins Incl Trop Dis 23, 42 (2017).
- Yang, M.-H. et al. Reduction of aluminum ion neurotoxicity through a small peptide application – NAP treatment of Alzheimer’s disease. Journal of Food and Drug Analysis 27, 551–564 (2019).
- Yiannopoulou, K. G. & Papageorgiou, S. G. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 6, 19–33 (2013).
- Zhang, J. et al. Davunetide improves spatial learning and memory in Alzheimer’s disease-associated rats. Physiology & Behavior 174, 67–73 (2017).